E-LIB Suche - Ergebnisse für: Duparc, S.

1

Modeling and simulation to evaluate pyronaridine exposure i..:

Fleckenstein, L. ; Methaneethorn, J. ; Duparc, S....
International Journal of Infectious Diseases. 16 (2012) - p. e159 , 2012

Link: https://doi.org/10.1016/..

2

Optimal dose finding for novel antimalarial combination the..:

Duparc, S. ; Lanza, C. ; Ubben, D...
Tropical Medicine & International Health. 17 (2012) 4 - p. 409-413 , 2012

Link: https://doi.org/10.1111/..

3

A Simplified Intravenous Artesunate Regimen for Severe Mala..:

Kremsner, P. G. ; Taylor, T. ; Issifou, S....
Journal of Infectious Diseases. 206 (2012) 4 - p. 622-622 , 2012

Link: https://doi.org/10.1093/..

4

LA SERVITUDE POUR DETTES:

Finley, I. ; Duparc, S.
Revue historique de droit français et étranger (1922-). 43 (1965) - p. 159-184 , 1965

Link: https://www.jstor.org/st..

5

Defining the next generation of severe malaria treatment: a..:

Achan, J ; Barry, A ; Leroy, D...
https://openaccess.sgul.ac.uk/id/eprint/116638/1/Defining%20the%20next%20generation%20of%20severe%20malaria%20treatment%20a%20target%20product%20profile.pdf. , 2024

Link: https://openaccess.sgul...

6

Temporal distribution of Plasmodium falciparum recrudescenc..:

Dahal, P ; Simpson, JA ; Abdulla, S...
issn:1475-2875. , 2022

Link: http://hdl.handle.net/11..

7

Haematological consequences of acute uncomplicated falcipar..:

Mansoor, R ; Commons, RJ ; Douglas, NM...
issn:1741-7015. , 2022

Link: http://hdl.handle.net/11..

8

Single-dose tafenoquine to prevent relapse of Plasmodium vi..:

Lacerda, MVG ; Llanos-Cuentas, A ; Krudsood, S...
doi:10.1056/nejmoa1710775. , 2020

Link: https://doi.org/10.1056/..

9

Factors affecting the electrocardiographic QT interval in m..:

Chan, XHS ; Win, YN ; Haeusler, IL...
doi:10.1371/journal.pmed.1003040. , 2020

Link: https://doi.org/10.1371/..

10

Pharmacogenetic assessment of tafenoquine efficacy in patie..:

St Jean, PL ; Koh, GCKW ; Breton, JJ...
doi:10.1097/fpc.0000000000000407. , 2020

Link: https://doi.org/10.1097/..

11

Safety, Tolerability, Pharmacokinetics, and Antimalarial Ac..:

Sinxadi, P ; Donini, C ; Johnstone, H...
issn:0066-4804. , 2020

Link: http://hdl.handle.net/11..

12

Competing risk events in antimalarial drug trials in uncomp..:

Dahal, P ; Simpson, JA ; Abdulla, S...
issn:1475-2875. , 2019

Link: http://hdl.handle.net/11..

13

Pyronaridine–Artesunate versus Mefloquine plus Artesunate f..:

Rueangweerayut, R ; Phyo, A ; Uthaisin, C...
doi:10.1056/NEJMoa1007125. , 2019

Link: https://doi.org/10.1056/..

14

Tafenoquine versus primaquine to prevent relapse of Plasmod..:

Llanos-Cuentas, A ; Lacerda, MVG ; Hien, TT...
doi:10.1056/nejmoa1802537. , 2019

Link: https://doi.org/10.1056/..

15

Quantifying primaquine effectiveness and improving adherenc..:

Thriemer, K ; Bobogare, A ; Ley, B...
doi:10.1186/s12936-018-2380-8. , 2018

Link: https://doi.org/10.1186/..